|
Gene: ATP9B |
Gene summary for ATP9B |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP9B | Gene ID | 374868 |
Gene name | ATPase phospholipid transporting 9B (putative) | |
Gene Alias | ATPASEP | |
Cytomap | 18q23 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O43861 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
374868 | ATP9B | CCI_1 | Human | Cervix | CC | 1.63e-06 | 6.40e-01 | 0.528 |
374868 | ATP9B | CCI_3 | Human | Cervix | CC | 1.02e-14 | 9.52e-01 | 0.516 |
374868 | ATP9B | AEH-subject1 | Human | Endometrium | AEH | 3.77e-04 | 2.25e-01 | -0.3059 |
374868 | ATP9B | AEH-subject3 | Human | Endometrium | AEH | 2.92e-03 | 1.87e-01 | -0.2576 |
374868 | ATP9B | AEH-subject4 | Human | Endometrium | AEH | 7.62e-04 | 3.28e-01 | -0.2657 |
374868 | ATP9B | AEH-subject5 | Human | Endometrium | AEH | 4.81e-06 | 2.79e-01 | -0.2953 |
374868 | ATP9B | EEC-subject2 | Human | Endometrium | EEC | 4.17e-04 | 2.39e-01 | -0.2607 |
374868 | ATP9B | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.53e-04 | -1.19e-01 | -0.1869 |
374868 | ATP9B | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.43e-03 | -1.18e-01 | -0.1875 |
374868 | ATP9B | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 7.57e-05 | -1.34e-01 | -0.1883 |
374868 | ATP9B | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 7.89e-06 | -2.62e-02 | -0.1934 |
374868 | ATP9B | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.46e-10 | -7.97e-03 | -0.1917 |
374868 | ATP9B | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.47e-05 | -4.78e-02 | -0.1916 |
374868 | ATP9B | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 4.42e-02 | 6.41e-01 | -0.138 |
374868 | ATP9B | RNA-P17T-P17T-4 | Human | Lung | IAC | 3.67e-03 | 5.56e-01 | 0.343 |
374868 | ATP9B | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.09e-12 | 5.70e-01 | -0.2116 |
374868 | ATP9B | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.92e-04 | 5.62e-01 | -0.2107 |
374868 | ATP9B | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.73e-07 | 4.77e-01 | -0.2119 |
374868 | ATP9B | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 3.11e-05 | 2.77e-01 | -0.0166 |
374868 | ATP9B | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.57e-06 | 2.97e-01 | -0.0132 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
GO:00068907 | Cervix | CC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 15/2311 | 52/18723 | 1.15e-03 | 9.39e-03 | 15 |
GO:00481939 | Endometrium | AEH | Golgi vesicle transport | 60/2100 | 296/18723 | 3.65e-06 | 9.79e-05 | 60 |
GO:00068908 | Endometrium | AEH | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 15/2100 | 52/18723 | 4.20e-04 | 4.46e-03 | 15 |
GO:004819313 | Endometrium | EEC | Golgi vesicle transport | 60/2168 | 296/18723 | 9.91e-06 | 2.17e-04 | 60 |
GO:000689013 | Endometrium | EEC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 15/2168 | 52/18723 | 5.90e-04 | 5.87e-03 | 15 |
GO:00481937 | Lung | IAC | Golgi vesicle transport | 49/2061 | 296/18723 | 2.35e-03 | 2.28e-02 | 49 |
GO:00159142 | Lung | IAC | phospholipid transport | 20/2061 | 96/18723 | 3.58e-03 | 3.00e-02 | 20 |
GO:00157482 | Lung | IAC | organophosphate ester transport | 26/2061 | 140/18723 | 5.22e-03 | 3.97e-02 | 26 |
GO:004819312 | Lung | AIS | Golgi vesicle transport | 46/1849 | 296/18723 | 1.32e-03 | 1.64e-02 | 46 |
GO:001591411 | Lung | AIS | phospholipid transport | 18/1849 | 96/18723 | 5.64e-03 | 4.76e-02 | 18 |
GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
GO:000689019 | Thyroid | PTC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 37/5968 | 52/18723 | 6.98e-09 | 1.75e-07 | 37 |
GO:0048193111 | Thyroid | ATC | Golgi vesicle transport | 189/6293 | 296/18723 | 9.58e-27 | 5.05e-24 | 189 |
GO:0006890110 | Thyroid | ATC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 37/6293 | 52/18723 | 3.45e-08 | 6.43e-07 | 37 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP9B | insertion | Frame_Shift_Ins | novel | c.2840_2841insTG | p.Phe949CysfsTer34 | p.F949Cfs*34 | O43861 | protein_coding | TCGA-BC-A10R-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Other, specify in noteschemoembolization | unknown | PD | ||
ATP9B | SNV | Missense_Mutation | novel | c.2759N>C | p.His920Pro | p.H920P | O43861 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP9B | SNV | Missense_Mutation | c.1934G>A | p.Arg645Lys | p.R645K | O43861 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-55-8507-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ATP9B | SNV | Missense_Mutation | c.1935G>T | p.Arg645Ser | p.R645S | O43861 | protein_coding | deleterious(0.01) | possibly_damaging(0.482) | TCGA-55-8507-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ATP9B | SNV | Missense_Mutation | c.7N>T | p.Asp3Tyr | p.D3Y | O43861 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.897) | TCGA-62-8398-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | CR | |
ATP9B | SNV | Missense_Mutation | c.2674N>A | p.Glu892Lys | p.E892K | O43861 | protein_coding | deleterious(0.03) | possibly_damaging(0.468) | TCGA-75-6214-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | PD | |
ATP9B | SNV | Missense_Mutation | rs749657455 | c.2839G>T | p.Ala947Ser | p.A947S | O43861 | protein_coding | deleterious(0.01) | probably_damaging(0.947) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
ATP9B | SNV | Missense_Mutation | c.1021N>T | p.Val341Phe | p.V341F | O43861 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
ATP9B | SNV | Missense_Mutation | c.431N>T | p.Thr144Ile | p.T144I | O43861 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ATP9B | SNV | Missense_Mutation | c.1711G>C | p.Ala571Pro | p.A571P | O43861 | protein_coding | deleterious(0.04) | benign(0.023) | TCGA-22-4599-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |